$PVCT News Article - Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10 and Keytruda for First-Line Stage III Melanoma at Melanoma Bridge 2022 https://marketwirenews.com/news-releases/prov...52475.html